BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21565405)

  • 1. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.
    Tsuboi K; Yokozawa T; Sakura T; Watanabe T; Fujisawa S; Yamauchi T; Uike N; Ando K; Kihara R; Tobinai K; Asou H; Hotta T; Miyawaki S
    Leuk Res; 2011 Oct; 35(10):1384-9. PubMed ID: 21565405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
    Löwenberg B; Muus P; Ossenkoppele G; Rousselot P; Cahn JY; Ifrah N; Martinelli G; Amadori S; Berman E; Sonneveld P; Jongen-Lavrencic M; Rigaudeau S; Stockman P; Goudie A; Faderl S; Jabbour E; Kantarjian H
    Blood; 2011 Dec; 118(23):6030-6. PubMed ID: 21976672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
    Dennis M; Davies M; Oliver S; D'Souza R; Pike L; Stockman P
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):461-9. PubMed ID: 22864876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
    Kantarjian HM; Martinelli G; Jabbour EJ; Quintás-Cardama A; Ando K; Bay JO; Wei A; Gröpper S; Papayannidis C; Owen K; Pike L; Schmitt N; Stockman PK; Giagounidis A;
    Cancer; 2013 Jul; 119(14):2611-9. PubMed ID: 23605952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
    Schwartz GK; Carvajal RD; Midgley R; Rodig SJ; Stockman PK; Ataman O; Wilson D; Das S; Shapiro GI
    Invest New Drugs; 2013 Apr; 31(2):370-80. PubMed ID: 22661287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
    Boss DS; Witteveen PO; van der Sar J; Lolkema MP; Voest EE; Stockman PK; Ataman O; Wilson D; Das S; Schellens JH
    Ann Oncol; 2011 Feb; 22(2):431-7. PubMed ID: 20924078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
    Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
    Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.
    Kantarjian HM; Sekeres MA; Ribrag V; Rousselot P; Garcia-Manero G; Jabbour EJ; Owen K; Stockman PK; Oliver SD
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):559-67. PubMed ID: 23763917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
    Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).
    Keizer RJ; Zandvliet AS; Beijnen JH; Schellens JH; Huitema AD
    Invest New Drugs; 2012 Aug; 30(4):1519-30. PubMed ID: 21626115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
    Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
    Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
    Walsby E; Walsh V; Pepper C; Burnett A; Mills K
    Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
    Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
    Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
    Hartsink-Segers SA; Zwaan CM; Exalto C; Luijendijk MW; Calvert VS; Petricoin EF; Evans WE; Reinhardt D; de Haas V; Hedtjärn M; Hansen BR; Koch T; Caron HN; Pieters R; Den Boer ML
    Leukemia; 2013 Mar; 27(3):560-8. PubMed ID: 22940834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
    Oke A; Pearce D; Wilkinson RW; Crafter C; Odedra R; Cavenagh J; Fitzgibbon J; Lister AT; Joel S; Bonnet D
    Cancer Res; 2009 May; 69(10):4150-8. PubMed ID: 19366807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
    Collins GP; Eyre TA; Linton KM; Radford J; Vallance GD; Soilleux E; Hatton C
    Br J Haematol; 2015 Sep; 170(6):886-90. PubMed ID: 25721307
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792.
    Sarvagalla S; Hsieh HP; Coumar MS
    Expert Opin Ther Pat; 2016 Jul; 26(7):751-5. PubMed ID: 27167102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
    Guo J; Anderson MG; Tapang P; Palma JP; Rodriguez LE; Niquette A; Li J; Bouska JJ; Wang G; Semizarov D; Albert DH; Donawho CK; Glaser KB; Shah OJ
    Pharmacogenomics J; 2009 Apr; 9(2):90-102. PubMed ID: 19188929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
    Kobayashi Y; Yamauchi T; Kiyoi H; Sakura T; Hata T; Ando K; Watabe A; Harada A; Taube T; Miyazaki Y; Naoe T
    Cancer Sci; 2015 Nov; 106(11):1590-5. PubMed ID: 26471242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.